# Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer

> **NCT04348032** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 152 (actual)

## Conditions studied

- Platinum-resistant Recurrent Ovarian Cancer

## Interventions

- **DRUG:** PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd
- **DRUG:** PLD 40mg/m2 ivgtt q4w

## Key facts

- **NCT ID:** NCT04348032
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-22
- **Primary completion:** 2021-01-28
- **Final completion:** 2022-06-30
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2022-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04348032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04348032, "Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04348032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*